Brind.

Qiagen received FDA clearance for its diagnostic product, QIAstat-Dx Rise, expanding access in the U.S. on September 3, 2025.

3 reports, 3 independent Updated Aug 27

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 3
Developments: 2
Repetition: 33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Qiagen received FDA clearance for its diagnostic product, QIAstat-Dx Rise, expanding access in the U.S. on September 3, 2025.

Who's involved

What this event is mainly about

Qiagen FDA

How it developed

Newest first. Tap a step to see who reported it.

Aug 27Qiagen achieved FDA listing for a new platform.1 source
- finanznachrichten.de
Sep 3Qiagen received FDA clearance for QIAstat-Dx Rise, expanding diagnostic access in the U.S.1 source
- Zacks

Keep exploring

The entities involved

Qiagen
company

Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Coverage

Newest first; wire copies grouped

Aug 27finanznachrichten.de
Sep 3ZacksQIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise QIAGEN N.V. QGEN announces the launch of QIAstat-Dx Rise — a version of the QIAstat-Dx automated syndromic testing system that offers
Sep 2Business WireQIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing U.S. market entry set to begin for QIAstat-Dx Rise – a version of QIAstat-Dx for